{"disease":{"id":"relapsed-or-refractory-follicular-lymphoma-relapsed-or-refractory-diffuse-large-b-cell-lymphoma","name":"relapsed or refractory follicular lymphoma relapsed or refractory diffuse large b cell lymphoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02600897","title":"A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}